Your browser doesn't support javascript.
loading
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
Conteduca, V; Wetterskog, D; Sharabiani, M T A; Grande, E; Fernandez-Perez, M P; Jayaram, A; Salvi, S; Castellano, D; Romanel, A; Lolli, C; Casadio, V; Gurioli, G; Amadori, D; Font, A; Vazquez-Estevez, S; González Del Alba, A; Mellado, B; Fernandez-Calvo, O; Méndez-Vidal, M J; Climent, M A; Duran, I; Gallardo, E; Rodriguez, A; Santander, C; Sáez, M I; Puente, J; Gasi Tandefelt, D; Wingate, A; Dearnaley, D; Demichelis, F; De Giorgi, U; Gonzalez-Billalabeitia, E; Attard, G.
Affiliation
  • Conteduca V; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
  • Wetterskog D; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Sharabiani MTA; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
  • Grande E; Research Data Management and Statistics Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Fernandez-Perez MP; Department of Medical Oncology, Hospital Ramón y Cajal, Madrid.
  • Jayaram A; Department of Hematology & Medical Oncology, Hospital Universitario Morales Meseguer, IMIB-Universidad de Murcia, Murcia.
  • Salvi S; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
  • Castellano D; Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Romanel A; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Lolli C; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Casadio V; Centre for Integrative Biology, University of Trento, Trento, Italy.
  • Gurioli G; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Amadori D; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Font A; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • Vazquez-Estevez S; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
  • González Del Alba A; Oncology Unit, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona.
  • Mellado B; Department of Medical Oncology, H. Universitario Lucus Augusti, Lugo.
  • Fernandez-Calvo O; Department of Medical Oncology, H.U. Son Espases Mallorca, Mallorca.
  • Méndez-Vidal MJ; Department of Medical Oncology, IDIBAPS Hospital Clinic, Barcelona.
  • Climent MA; Department of Medical Oncology, Hospital de Orense, Orense.
  • Duran I; Department of Medical Oncology, Hospital Universitario Reina Sofía, Córdoba.
  • Gallardo E; Department of Medical Oncology, Instituto Valenciano de Oncología Valencia, Valencia.
  • Rodriguez A; Department of Medical Oncology, Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla.
  • Santander C; Department of Medical Oncology, H.U. Parc Taulí, Sabadell, Barcelona.
  • Sáez MI; Department of Medical Oncology, Hospital de León, León.
  • Puente J; Department of Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza.
  • Gasi Tandefelt D; Department of Medical Oncology, Hospital Regional y Hospital Virgen de la Victoria, Malaga.
  • Wingate A; Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Spain.
  • Dearnaley D; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
  • Demichelis F; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK.
  • Attard G; Centre for Integrative Biology, University of Trento, Trento, Italy.
Ann Oncol ; 28(7): 1508-1516, 2017 Jul 01.
Article in En | MEDLINE | ID: mdl-28472366
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylthiohydantoin / Receptors, Androgen / Biomarkers, Tumor / Antineoplastic Agents, Hormonal / Prostatic Neoplasms, Castration-Resistant / Circulating Tumor DNA / Androstenes Type of study: Clinical_trials / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged80 Country/Region as subject: Europa Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2017 Type: Article Affiliation country: United kingdom
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylthiohydantoin / Receptors, Androgen / Biomarkers, Tumor / Antineoplastic Agents, Hormonal / Prostatic Neoplasms, Castration-Resistant / Circulating Tumor DNA / Androstenes Type of study: Clinical_trials / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged80 Country/Region as subject: Europa Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2017 Type: Article Affiliation country: United kingdom